Celera Appoints Jean Amos Wilson, Ph.D., As Vice President of Laboratory Operations at Berkeley Heartlab
Celera (NASDAQ:CRA) today announced the appointment of Jean Amos Wilson, Ph.D., as Vice President of Laboratory Operations at Berkeley HeartLab (BHL), effective August 11, 2008. Dr. Amos Wilson will report to Kathy Ordonez and oversee all laboratory operations at BHL, working in collaboration with Arthur Baca, M.D., BHL’s Medical Director.
Dr. Amos Wilson has over thirty years of experience in clinical laboratory management and molecular genetics. Most recently, she was Senior Director of Genetic Services at Sequenom, where she led the technical direction of its clinical research (CRO) organization that provides high throughput molecular testing for research and diagnostics. Prior to Sequenom, Dr. Amos Wilson served as the Scientific Director of Human Genetics at Focus Diagnostics, and before that, she was Director, Molecular Genetics at Specialty Laboratories, both commercial clinical laboratories.
Dr. Amos Wilson holds a Bachelor of Science degree, Master of Science degree and Doctor of Philosophy in Genetics, all from The Ohio State University, Columbus, OH. She is Board certified and is licensed as a Laboratory Director in California and New York. Dr. Amos Wilson is a Fellow of the American College of Medical Genetics, and has over sixty publications in the field of genetics. She is also a member of the board of directors of the American Board of Medical Genetics, Chair of the Association for Molecular Pathology Professional Relations Committee and an Area Committee Advisor for the Clinical Laboratory Standards Institute (CLSI).
“Jean is an innovative and entrepreneurial leader who has managed several commercial laboratories, while providing technical direction to the development and validation of new test methods,” said Kathy Ordonez, Chief Executive Officer of Celera. “We are now expanding the menu of genetic tests offered through BHL and are delighted to gain access to Jean’s breadth of experience in clinical laboratory management and genetic testing.”
“This is a very exciting time to join Celera as it expands its test offering in genetics through Berkeley HeartLab,” said Jean Amos Wilson, Ph.D., Vice President of Laboratory Operations at Celera. “These developments, coupled with a full pipeline of potential new tests based on Celera’s proprietary discoveries, present a terrific opportunity for the future.”
Celera is a healthcare business delivering personalized disease management through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and improve patient management. Celera also commercializes a wide range of molecular diagnostic products through its strategic alliance with Abbott and has licensed other relevant diagnostic technologies developed to provide personalized disease management in cancer and liver diseases. Information about Celera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.celera.com.
Copyright(C) 2008. Celera Corporation. All Rights Reserved. Celera is a registered trademark of Celera Corporation or its subsidiaries in the U. S. and/or certain other countries.